Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
User rating: 4.3 / 5 after 8 vote(s)
Sirtris Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.
Full story »
|

PhysOrg Forum
Video
Editorials
Free Magazines
Newsletter
Goto Archive
Suggest a story idea
Send feedback